Novo Nordisk has announced the filing of 14 new lawsuits against the sale of unapproved compounded drugs claiming to contain semaglutide.

Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit today, but rising competition is ...

Novo Nordisk (NVO) said Wednesday it will cut costs as it faces increasing competition from Eli Lilly (LLY) and generic ...

Novo Nordisk, the maker of Wegovy, plans to cut costs and refocus commercially after a $95 billion stock loss. The company's market cap has dropped to around $212 billion.

Glencore Earnings Fall on Lower Coal Prices, Copper Production Challenges The commodities giant said the results reflect lower coal prices and a drop in copper production following operational ...

Semaglutide--which is marketed as Wegovy for weight-loss and Ozempic for diabetes--had been in short supply as the company raced to increase production and meet surging demand. But the drug came off ...

Maziar Mike Doustdar will take the helm as CEO tomorrow, with the firm facing tough questions from investors about how it can stay competitive.

Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity ...

Pedersen and Maggie Fick COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk said on Wednesday it will sharpen its commercial ...

Wegovy-maker Novo Nordisk reported second-quarter sales up 18% on Wednesday, below initial analyst expectations, after a ...